Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Soysal, M. E.
Right arrow Articles by Ozer, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soysal, M. E.
Right arrow Articles by Ozer, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 16, No. 5, 931-939, May 2001
© 2001 European Society of Human Reproduction and Embryology

A randomized controlled trial of goserelin and medroxyprogesterone acetate in the treatment of pelvic congestion

Mehmet Emin Soysal1,4, Seyide Soysal1, Kubilay Vicdan2 and Suzan Ozer3

1 Department of Obstetrics and Gynecology, Pamukkale University Medical Center, Denizli, 2 Department of Obstetrics and Gynecology, Bayindir Medical Center, Ankara and 3 Department of Psychiatry, Hacettepe University School of Medicine, 06200, Ankara, Turkey

Following identification of the proportion of pelvic congestion among symptomatic patients complaining of chronic pelvic pain, and in a totally asymptomatic group of patients requesting tubal ligation, the efficiency of goserelin acetate versus medroxyprogesterone acetate was compared objectively using pelvic venogram scores, and subjectively by symptom resolution, improvement of psychological status and sexual functioning in a prospective randomized trial in 47 patients with pure pelvic congestion syndrome. Patients received either goserelin acetate (3.6 mg/month for 6 months) or medroxyprogesterone acetate (MPA; 30 mg/day for 6 months). Among patients with chronic pelvic pain, those with pure pelvic congestion were mostly parous, had the most severe pelvic signs and symptom scores, lowest rates of sexual functioning, and higher states of anxiety and depression as compared with others. At 1 year after treatment, goserelin remained superior to MPA in terms of pelvic venographic improvement as an objective measure. In alleviation of signs and symptomatology, improvement of sexual functioning and reduction of anxiety and depressive states as subjective measures, goserelin acetate achieved a statistically significant advantage (P = 0.0001) compared with MPA.

Key words: goserelin acetate/medroxyprogesterone acetate/pelvic congestion syndrome

4 To whom correspondence should be addressed at: Department of Obstetrics and Gynecology, Pamukkale University Medical Center, 20100, Denizli, Turkey. E-mail: mesoysal{at}anet.net.tr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
O. Taskin, S. Kursun, M. Simsek, and B. Trak
Pelvic congestion/chronic pain dynamics
Hum. Reprod., April 1, 2002; 17(4): 1127 - 1127.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.